DK1330468T3 - Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider - Google Patents

Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider

Info

Publication number
DK1330468T3
DK1330468T3 DK01969729T DK01969729T DK1330468T3 DK 1330468 T3 DK1330468 T3 DK 1330468T3 DK 01969729 T DK01969729 T DK 01969729T DK 01969729 T DK01969729 T DK 01969729T DK 1330468 T3 DK1330468 T3 DK 1330468T3
Authority
DK
Denmark
Prior art keywords
hydroxy
treatment
oxido
progesterone
sulfur analogs
Prior art date
Application number
DK01969729T
Other languages
Danish (da)
English (en)
Inventor
Gerardo Burton
Carlos P Lantos
Adriana Silvia Veleiro
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of DK1330468T3 publication Critical patent/DK1330468T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0073—Sulfur-containing hetero ring
    • C07J71/0078—Sulfur-containing hetero ring containing only sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01969729T 2000-09-18 2001-09-17 Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider DK1330468T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00119495 2000-09-18
PCT/EP2001/010750 WO2002022647A1 (en) 2000-09-18 2001-09-17 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids

Publications (1)

Publication Number Publication Date
DK1330468T3 true DK1330468T3 (da) 2007-11-05

Family

ID=8169775

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01969729T DK1330468T3 (da) 2000-09-18 2001-09-17 Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider

Country Status (14)

Country Link
US (2) US7053228B2 (ja)
EP (1) EP1330468B1 (ja)
JP (1) JP2004509132A (ja)
AT (1) ATE368683T1 (ja)
AU (1) AU8988901A (ja)
CA (1) CA2419887C (ja)
CY (1) CY1107756T1 (ja)
DE (1) DE60129725T2 (ja)
DK (1) DK1330468T3 (ja)
ES (1) ES2288987T3 (ja)
IL (2) IL154775A0 (ja)
PT (1) PT1330468E (ja)
SI (1) SI1330468T1 (ja)
WO (1) WO2002022647A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8988901A (en) * 2000-09-18 2002-03-26 Applied Research Systems Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids
AU2002218179B2 (en) * 2000-09-18 2006-11-16 Merck Serono Sa Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
CN102190607A (zh) * 2010-03-15 2011-09-21 北京化工大学 一种农药除草剂中间体乙磺酰基乙腈的绿色合成方法
EP2413115A1 (en) * 2010-07-30 2012-02-01 Technische Universiteit Eindhoven Generating a control signal based on acoustic data

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910191A (en) * 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
NZ314644A (en) * 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
EP1136075B1 (en) 1997-09-21 2003-01-15 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
HU230045B1 (hu) * 1999-04-23 2015-06-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Bőrgyógyászati alkalmazásra szolgáló nem vizes gyógyszerkészítmény
AU8988901A (en) 2000-09-18 2002-03-26 Applied Research Systems Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids
AU2002218179B2 (en) 2000-09-18 2006-11-16 Merck Serono Sa Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)

Also Published As

Publication number Publication date
DE60129725T2 (de) 2007-12-06
AU8988901A (en) 2002-03-26
US20040029846A1 (en) 2004-02-12
SI1330468T1 (sl) 2007-10-31
ES2288987T3 (es) 2008-02-01
CA2419887C (en) 2009-11-10
JP2004509132A (ja) 2004-03-25
ATE368683T1 (de) 2007-08-15
CA2419887A1 (en) 2002-03-21
IL154775A (en) 2010-12-30
WO2002022647A1 (en) 2002-03-21
PT1330468E (pt) 2007-09-13
US20050222104A1 (en) 2005-10-06
US7479486B2 (en) 2009-01-20
EP1330468A1 (en) 2003-07-30
IL154775A0 (en) 2003-10-31
EP1330468B1 (en) 2007-08-01
DE60129725D1 (de) 2007-09-13
CY1107756T1 (el) 2013-09-04
US7053228B2 (en) 2006-05-30

Similar Documents

Publication Publication Date Title
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DK1309593T3 (da) Substituerede pyrazoler
ATE247464T1 (de) Neue fettanaloge zur behandlung der fettleibigkeit
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
EA200900663A1 (ru) Лечение синдрома "сухого глаза"
DE50115490D1 (de) Kosmetische zusammensetzung zur behandlung von alternder und/oder gestresster haut
DK1309592T3 (da) Substituerede pyrazoler
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
ATE303156T1 (de) Verwendung von gnrh-analogue zur behandlung der harninkontinenz
MY135841A (en) Novel benzodioxoles
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
MY142044A (en) Endoparasiticidal compositions for topical application
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne
DE602006012115D1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
SE0004101D0 (sv) New use
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
DE60135972D1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
ATE347536T1 (de) Chlorsilanblends zur behandlung von quarzfuellstoffen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen